Co-development Deals in Pharmaceuticals and Biotechnology 2016-2024


Co-development Deals in Pharmaceuticals and Biotechnology | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Comprehensive deal directory 2016 to 2024

Publication date
March 2024
Number of pages
Product type
Research report
Available formats
PDF document
Report edition
4 - fully revised and updated

Co-development Deals in Pharmaceuticals and Biotechnology provides a detailed understanding and analysis of how and why companies enter co-development deals.

Fully revised and updated, the report provides details of co-development deals from 2016 to 2024.

The report provides access to co-development deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of co-development deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual co-development contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of co-development dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview and analysis of the trends in co-development as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of co-development deals.

Chapter 4 provides a review of the leading co-development deals since 2016. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 25 most active co-development dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand. 

Chapter 6 provides a comprehensive and detailed review of co-development deals organized by company A-Z, therapy, technology and industry type signed and announced since 2016 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the co-development deal.

The deal directory includes a comprehensive listing of all co-development deals announced since 2016. Each listing is organized as a deal directory by company A-Z, therapeutic area and technology type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in co-development dealmaking since 2016.

In conclusion, this report provides everything a prospective dealmaker needs to know about co-development alliances.


Key benefits

Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse co-development deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time


Report scope

Co-development Deals in Pharmaceuticals and Biotechnology is intended to provide the reader with an in-depth understanding of the co-development trends and structure of deals entered into by leading biopharma companies worldwide.

Co-development Deals in Pharmaceuticals and Biotechnology includes:

  • Trends in co-development dealmaking in the biopharma industry
  • Overview of co-development deal structure
  • Directory of co-development deal records covering pharmaceutical and biotechnology
  • The leading co-development deals by value
  • Most active co-development dealmakers
  • The leading co-development partnering resources


In Co-development Deals in Pharmaceuticals and Biotechnology, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type


Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Co-development Deals in Pharmaceuticals and Biotechnology provides comprehensive access to available records for co-development deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the rights granted or optioned?
  • What rights are granted by the agreement?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are intellectual property rights handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Co-development Deals in Pharmaceuticals and Biotechnology provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse co-development deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in co-development dealmaking

2.1. Introduction

2.2. Definition of co-development deal

2.3. Trends in co-development deals since 2016

2.3.1. Co-development dealmaking by year, 2016-2024

2.3.2. Co-development dealmaking by phase of development, 2016-2024

2.3.3. Co-development dealmaking by industry sector, 2016-2024

2.3.4. Co-development dealmaking by therapy area, 2016-2024

2.3.5. Co-development dealmaking by technology type, 2016-2024

2.3.6. Co-development dealmaking by most active company, 2016-2024

2.4. Reasons for entering into co-development partnering deals

2.5. The future of co-development deals


Chapter 3 – Overview of co-development deal structure

3.1. Introduction

3.2. Co-development agreement structure


Chapter 4 – Leading co-development deals

4.1. Introduction

4.2. Top co-development deals by value


Chapter 5 – Top 25 most active co-development dealmakers

5.1. Introduction

5.2. Top 25 most active co-development dealmakers


Chapter 6 – Co-development deals including contracts directory

6.1. Introduction

6.2. Co-development deals with contracts 2016-2024


Deal directory

Deal directory – co-development dealmaking by companies A-Z

Deal directory – co-development dealmaking by therapy area

Deal directory – co-development dealmaking by technology type


About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from Current Partnering



Figure 1: Definition of co-development deal

Figure 2: Trends in co-development deal announcements, 2016-2024

Figure 3: Co-development deals signed at each phase of development, 2016-2024

Figure 4: Co-development deals by industry sector, 2016-2024

Figure 5: Co-development deals by therapy area, 2016-2024

Figure 6: Co-development deals by technology type, 2016-2024

Figure 7: Top 25 most active co-development dealmakers, 2016-2024

Figure 8: Top co-development deals by value, 2016-2024

Figure 9: Most active co-development dealmakers, 2016-2024

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.


Total Trust

Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.

1ST Biotherapeutics, 2seventy bio, 3B Pharmaceuticals, 3DMed, 3D Systems, 4basebio Discovery, 4D Molecular Therapeutics, 10X Genomics, A2A Pharmaceuticals, Abbisko Therapeutics, Abbvie, AbCellera Biologics, AbelZeta Pharma, ABL Bio, Abpro, AbVacc, ABVC BioPharma, ACADIA Pharmaceuticals, Acceleron Pharma, Accellix, Accent Therapeutics, Accord Healthcare, ACEA Biosciences, Ache, AC Immune, Acrivon Therapeutics, Adaptimmune, Aduro BioTech, Advaxis, Affibody, Affini-T Therapeutics, AFT Pharmaceuticals, Agena Bioscience, Agendia, Agilent Technologies, Agios Pharmaceuticals, AIkido Pharma, AimedBio, Ainos, Ajinomoto, Akcea Therapeutics, Akoya Biosciences, Albany Molecular Research, Alector, Alexion Pharmaceuticals, Algenex, Aliada Therapeutics, Alkem Laboratories, Allele Biotechnology and Pharmaceuticals, Alligator Bioscience, Alnylam Pharmaceuticals, Alphamab Biopharmaceuticals, Alteogen, Alternavida, Altor BioScience, Altos Group, Alvotech, Alytas Therapeutics, Alzheimer's Drug Discovery Foundation, Amerimmune, Amgen, Amyris, Analog Devices, Anavex Life Sciences, AnchorDx, AnGes MG, AnHeart Therapeutics, Ankarys Therapeutics, Apellis Pharmaceuticals, Apmonia Therapeutics, Apobiologix, Apollomics, Applied DNA Sciences, Applied StemCell, Aprecia Pharmaceuticals, Aptar Pharma, Aptevo Therapeutics, Aquestive Therapeutics, Arbele, Arbor Biotechnologies, Arcellx, Arcturus Therapeutics, Arcus Biosciences, Ardeagen, Arecor, Arrowhead Pharmaceuticals, Artes Biotechnology, Artios Pharma, Arvinas, Ascenion, Ascensia Diabetes Care, Ascentage Pharma, ASC Therapeutics, ASKA Pharmaceuticals, Aspect Biosystems, Astellas Pharma, AstraZeneca, Athena Pharmaceutiques, Atomwise, Atropos Therapeutics, Augmenta, AUM Biosciences, Aurealis Therapeutics, Autotelic BIO, Avacta, Avactis Biosciences, Avalon GloboCare, Avellino Labs, Avicanna, Aviragen Therapeutics, AXIM Biotechnologies, Azitra, Azos Bio, Bach Biosciences, Banyan Biomarkers, Bayer, Beam Therapeutics, BehaVR, BeiGene, Beijing Defengrei Biotechnology, Beijing Sun-Novo Pharmaceutical Research, Belharra Therapeutics, Berry Genomics, Betta Pharmaceuticals, Beyondspring Pharmaceuticals, Bharat Biotech, Bill and Melinda Gates Foundation, Bio-Rad Laboratories, Bio-Techne, BioAtla, BioComo, BiocurePharm, Biocytogen, Biodextris, BioGemex, Biogen, BioInvent, BioKey, BioLabs, BioLegend, BioMotiv, Biomunex Pharmaceuticals, BioNano Genomics, BioNova Pharmaceuticals, Bionpharma, BioNTech, BioNxt Solutions, BiosanaPharma, BioSerenity, BioSun Pharmed, BioVaxys, Bioventus, Blake Insomnia Therapeutics, Blau Pharma, Bloomios, Blueberries Medical, Bluebird Bio, Blueprint Medicines, Blue Water Vaccines, BodyLogicMD, Boehringer Ingelheim, Bolt Biotherapeutics, Boryung Pharmaceutical, BrickBio, BridgeBio Pharma, Bridge Biotherapeutics, Brigham and Women's Hospital, BrighGene Biomedical, Bristol-Myers Squibb, Burning Rock, Cadila Pharmaceuticals, California Institute for Biomedical Research, Cambrooke Therapeutics, Can-Fite BioPharma, Cancer Genetics, CannaSoul Analytics, Cannassure Therapeutics, Capsida Biotherapeutics, Captor Therapeutics, Caraway Therapeutics, CARB-X, Carina Biotech, Carl Zeiss Meditec, CBT Pharmaceuticals, Cedars-Sinai Medical Center, Celgene, Cellastra, Cellgen Diagnostics, Celltrion, Cellular Biomedicine, Cellvera, Censa Pharmaceuticals, Cerenis Therapeutics, Cerulean Pharma, Champions Oncology, Cheil Pharm, ChemDiv, Chi-Med, Chiesi Global Rare Diseases, China National Biotech Group (CNBG), Chinese Academy of Sciences, Chiome Bioscience, CicloMed, Cidara Therapeutics, CimCure, Cipla, Ciron Drugs & Pharmaceuticals, Closed Loop Medicine, Coave Therapeutics, Codagenix, Coeptis Pharmaceuticals, Coherus Biosciences, Collplant, Complement Pharma, Confo Therapeutics, Context Therapeutics, Contineum Therapeutics, Cosmo Pharmaceuticals, CRISPR Therapeutics, CrystalGenomics, CSL, CStone Pharmaceuticals, CtM Biotech, Cue Biopharma, Cullgen, Cullinan Oncology, CURE Pharmaceutical, CureVac, Cyagen Biosciences, Cygnus, CytomX Therapeutics, Dabur, Daewoong Pharmaceutical, Daiichi Sankyo, Dana-Farber Cancer Institute, Dance Biopharm, DaRui Biotech, Debiopharm, Denali Therapeutics, Department of Defense, Department of Health and Human Services, DePuy, Dermavant Sciences, Dicerna Pharmaceuticals, DigiLab, DotBio, Dr. Falk Pharma, Dryworld, DSM, DualityBio, Duke-NUS Graduate Medical School Singapore, Dyadic International, Eikon Therapeutics, EirGenix, Eisai, Elektrofi, ElevateBio, EligoChem, Eli Lilly, Elite Pharmaceuticals, Elpis Biomed, Emergent BioSolutions, Emmaus Life Sciences, Empirico, Enigma Biomedical, Ensysce Biosciences, Entasis Therapeutics, Enterome Bioscience, EpiVax Therapeutics, Especificos Stendhal, EspeRare Foundation, Esperovax, Essex Bio-Technology, Estee Lauder, Evidation Health, Evonetix, Evotec, EVQLV, Evvivax, Eybna Technologies, Eyegene, Fabric Genomics, FairJourney Biologics, Fannin, Farmacore Biotechnology, Fate Therapeutics, Fermbox Bio, Ferrer International, FineImmune Biotechnology, Firebrand Therapeutics, Flightpath Biosciences, Flowerkist, Foghorn Therapeutics, Foresee Pharmaceuticals, Formosa Pharmaceuticals, Forsyth Institute, Fosun Pharmaceutical, Fresenius Kabi Pharmaceuticals, Frontier Medicines, Fusion Pharmaceuticals, Fuzionaire Radioisotope Technologies, Galderma, GB Sciences, Gedeon Richter, GE Healthcare, Genentech, GeneQuantum Healthcare, Generate Biomedicines, Genethon, Geninus, Genmab, Genome Institute of Singapore, Genomic Testing Cooperative, Genoptix, GenScript Biotech, Genzyme, Georgia State University Research Foundation (GSURF), Gicell, GigaMune, Gilead Sciences, Ginkgo BioWorks, Glatt Group, Glimpse Group, Global Antibiotic Research and Development Partnership, Global Dx, Glytherix, GMSbiotech, GoodRx, GPCR Therapeutics, Great Bay Bio, Greenlight Biosciences, GSK, GTEC Holdings, Guangzhou Boji Medical Biotechnological, H3 Biomedicine, HaloVax, Hamlet Pharma, HanAll Pharmaceuticals, HanchorBio, Hanmi Pharmaceutical, Happify Health, Harbour Biomed, Harvard University, HDT Bio, HebeCell, HEC Pharm, Helsinn Healthcare, Helsinn Therapeutics, Henlius Biotech, HiFiBio, High Beauty, Hikma Pharmaceuticals, Histogen, Hitachi Chemical, HK inno.N, Hollister Biosciences, Horizon Discovery, Hoth Therapeutics, HTC ChemRar, Hummingbird Bioscience, Hyloris Pharmaceuticals, I-mab, i2c Pharmaceutical Services, IACTA Pharmaceuticals, iBio, IBM Watson Health, Icagen, Idorsia, Iktos, Illumina, Immatics Biotechnologies, ImmBio, ImmunityBio, Immunocore, IMPACT Therapeutics, Impression Healthcare, Incyte, Indivumed, Infex Therapeutics, InflaRx, Innate Pharma, Innovent Biologics, Inovio Pharmaceuticals, Insilico Medicine, Insitro, InSitu Biologics, Inspirna, Institut Gustave Roussy, Institut Pasteur, Integrated Cannabis Company, IntelGenx, Intellia Therapeutics, International Flavors and Fragrances, Intravacc, InventisBio, inviCRO, Ionis Pharmaceuticals, iPharma, Ipsen, Ironwood Pharmaceuticals, iTeos Therapeutics, iTolerance, Ix Therapeutics, Jabez Pharma, Jacobio Pharmaceuticals, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Japan Tobacco, JCR Pharmaceuticals, Jeffrey Modell Foundation, Jiangsu Carephar Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu NHWA Pharmaceutical, Johns Hopkins University, Johnson & Johnson Innovation, JSR, Junshi Biosciences, JW Therapeutics, Kadimastem, Kaiku Health, Kainos Medicines, Kaken Pharmaceutical, Kalos Therapeutics, Kanabo Research, Kartos Therapeutics, Kite Pharma, Klaria, Kleo Pharmaceuticals, KSQ Therapeutics, Kudo Biotechnology, Kyorin Pharmaceutical, Kyowa Hakko Kirin, Kyverna Therapeutics, Laboratoires Thea, Laboratorios Ordesa, Laekna, Lannett, Launch Therapeutics, Laxai Pharma, Lead Discovery Center, LegoChem Biosciences, Leon-nanodrugs, LEO Pharma, Les Laboratoires Servier, Leucid Bio, Leukemia & Lymphoma Society, LG Life Sciences, LianBio, LifeLink Foundation, LifeLiver, Life Magnetics, LineaRx, Lipidor, Lipigon Pharmaceuticals, Livzon Pharmaceutical, Louisiana State University, Loxo Oncology, LTS Lohmann Therapie-Systeme, Lumen Biomedical, Lundbeck, Luye Pharma Group, Lyell Immunopharma, Lygos, MAKScientific, MangoGen Pharma, MASORI Therapeutic, Massachusetts General Hospital, MaSTherCell, Max-Delbruck Center for Molecular Medicine, Mayo Clinic, McQuade Center for Strategic Research and Development, MD Anderson Cancer Center, Meatable, Mechelen, MediciNova, Medigen Biotechnology, Medigen Vaccine Biologics, MedImmune, Medocann Pharma, Medolife Rx, Medtronic, Medytox, MEI Pharma, Melinta Therapeutics, Menarini, Mercachem, Merck and Co, Merck KGaA, Merdury Biopharmaceutical, Meridian Laboratories, Mersana Therapeutics, Merus, Merz, Mesoblast, Metagenomi, Metalabs, MetP Pharma, Microbiotix, Mie University, Millennium, Mirati Therapeutics, Mission Bio, Mission Health, Mochida Pharmaceutical, Moderna, Molecular Partners, Molecular Templates, Mologen, Momenta Pharmaceuticals, Morphic Therapeutic, MorphoSys, Mount Sinai Medical Center, MSD Wellcome Trust Hilleman Laboratories, Mundipharma, Mundo Sano, Mydecine Group, MYOS, Nanion, Nanobiotix, NanoSmart Pharmaceuticals, NantKwest, National Cancer Institute, National Immunobiological Company, National Institutes of Health, Navitor Pharmaceuticals, Ncardia, NEC, Nektar Therapeutics, Neo Gene Pharm, Neptune Technologies & Bioressources, Neptune Wellness Solutions, Nestle Health Science, Neuracle Genetics, Neuraly, Neuro3 Therapeutics, Neurochase, Neurocrine Biosciences, Neurophth Therapeutics, Newly Institute, Newsoara Biopharma, NextCure, NFL Biosciences, NGK Spark PLug, Nipro Corporation, Nkarta Therapeutics, Noile-Immune Biotech, Noramco, Notable Labs, NOTA Laboratories, Novartis, Novel351k, NovImmune, Novoheart, Novo Nordisk, Nuance Pharma, Numab, Nurix Therapeutics, NurrOn Pharmaceuticals, NutriQuest, Ocean Genomics, Ocugen, Ocumension Therapeutics, OncoC4, Oncologie, Oncology Pharma, Oncology Venture, Oncozen, OncoZenge, One BioMed, ONK Therapeutics, Ono Pharmaceutical, Onward Therapeutics, Open Book Extracts, OPKO Health, Optum, Orano Med, Ordaos Bio, Orgenesis, Ori Biotech, Orient Pharma, Orion, Orizuru Therapeutics, Osaka University, OSE Immunotherapeutics, Otsuka, Oxford BioMedica, Oxis International, P-Chip, PACT Pharma, Paige, Palisade Bio, Pall Corporation, Partex Group, Pasithea Therapeutics, Pathalys Pharma, PDS Biotechnology, PeptiDream, PeptiGrowth, Perlara, Pfizer, Pharmanovia, PhaseBio Pharmaceuticals, Phillips-Medisize, Phlow, PhoreMost, Pieris Pharmaceuticals, Pierre Fabre, Pleco Therapeutics, Plexium, Polyphor, Portal Bioscience, Precise Biometrics, Precision NanoSystems, Premier Inc, Prestige BioPharma, Prevail Therapeutics, PreventionGenetics, Procare Health, Project to Accelerate New Treatments for Tuberculosis, Promethera Biosciences, Prometheus Biosciences, Promore Pharma, Propeller Health, Protagonist Therapeutics, Protein Sciences, Proteovant Therapeutics, Provention Bio, Pulmatrix, Purdue Pharma, Pure Extracts Technologies, Pure Protein, QED Therapeutics, Qiagen, Qilu Pharmaceutical, Quadira Biosciences, Quark Pharmaceuticals, Quell Therapeutics, Quratis, Rainbow Medical, Rakuten Medical, Rambam Medical Center, Ramot at Tel Aviv University, Rebus Biosystems, RedHill Biopharma, RefleXion Medical, Refuge Biotechnologies, Regen BioPharma, Regeneron Pharmaceuticals, RemeGen, Repare Therapeutics, Replicel Life Sciences, RespireRx Pharmaceuticals, Retrophin, ReveraGen BioPharma, Reyon Pharmaceuticals, Rgene, Rigel Pharmaceuticals, Roche, Roche Diagnostics, Rocket VR Health, RoosterBio, Rosalind, Royal Philips Electronics, Sajo Consulting, Salus Pharma, Samsung Biologics, Sandoz, SanegeneBio, Sanofi, Santen Pharmaceutical, Sarepta Therapeutics, SATT Nord, SATT Paris-Saclay, Scandinavian Health, Scandion Oncology, Schrodinger, SciClone Pharmaceuticals, SCM Pharma, Scorpion Therapeutics, Scottish Enterprise, Scribe Therapeutics, Seagen, Seattle Genetics, Secarna Pharmaceuticals, Seikagaku, Seipasa, Selvita, Sen-Jam Pharmaceutical, Senai Cimatec, Sensorion, Sentieon, Sentinel Oncology, SequMed, Serum Institute of India, SFJ Pharmaceuticals, Shandong Boan Biological Technology, Shandong Luoxin Pharma, Shanghai Ark Biopharmaceutical, Shanghai Institute of Materia Medica, Sheba Medical Center, Shimadzu, Siemens Healthineers, Simcere Pharmaceuticals, Similis Bio, Sinergium Biotech, Sirenas, Sirnaomics, SiSaf, SK Bioscience, SN BioScience, Sofregen Medical, Sonova, Sorrento Therapeutics, Sosei, Spectrum Pharmaceuticals, Spencer Health Solutions, STADA Arzneimittel, Staidson (Beijing) BioPharmaceuticals, Stealth BioTherapeutics, StemoniX, Stempeutics, Stockton Group, Stoke Therapeutics, StrideBio, SUDA Pharmaceuticals, Sumitomo Dainippon Pharma, SunGen, Sunny Pharmtech, Sunovion Pharmaceuticals, Supernus Pharmaceuticals, Sutro Biopharma, Swedish Orphan Biovitrum, Symbasis, Synpromics, Tachyon Therapeutics, Tactical Relief, Taiho, TaiwanBio Therapeutics, TaiwanJ Pharmaceuticals, Takeda Pharmaceutical, Takis Biotech, TALLC, Tango Therapeutics, Tarveda Therapeutics, Tavotek Biotherapeutics, TC BioPharm, Teijin, Telix Pharmaceuticals, Tetra Bio-Pharma, Teva Pharmaceutical Industries, Texas A&M University, TFF Pharmaceuticals, TG Therapeutics, The Nutraceutical Medicine Company, Therapyx, Theravance, Thermo Fisher Scientific, Tianjin CanSino Biotechnology, Tilray, TOMA Biosciences, Torii Pharmaceutical, Torrey Pines Investment, TransCode Therapeutics, Transgene, Transplant Genomics, Treventis, Trovita Health Science, TRPharm, Turnstone Biologics, Twist Bioscience, TYG Oncology, UbiQ, UCB, UGISense, Ultragenyx Pharmaceuticals, Uni-Bio Science, United Therapeutics, Univercells, Universal Cells, University of Bonn, University of Copenhagen, University of Heidelberg, University of Massachusetts Medical School, University of North Texas, Univo Pharmaceuticals, Vaccitech, Valent Biosciences, Valneva, Vasomune Therapeutics, Vaximm, Vaxine, Vaxxas, VectorBuilder, Velabs Therapeutics, VenatoRx, Ventana Medical Systems, Veranome Biosystems, Veraxa Biotech, Vertex Pharmaceuticals, ViaCyte, Vical, Vici Health Sciences, Vifor-Fresenius Medical Care Renal Pharma, Vir Biotechnology, vivoPharm, Voltron Therapeutics, Voluntis, Voyager Therapeutics, Vyant Bio, VyGen-Bio, Wanchunbulin, WAVE Life Sciences, Weill Cornell Medical College, WellDoc, Wellmarker Bio, Westlake Pharma, Willow Biosciences, W L Gore, WuXi Biologics, Wyss Institute, X4 Pharmaceuticals, Xbiome, Xbrane Bioscience, Xencor, Xenon Pharmaceuticals, XERIS Pharmaceuticals, Xortx Therapeutics, Xylonix, Yabao Pharmaceutical, Yatiri Bio, Yingli Pharma, Yisheng Biopharma, YOFOTO (China) Health Industry, Yonsei University Severance Hospital, Yuhan Corporation, Yunnan Walvax Biotech, YVY Life Sciences, ZAI Laboratory, Zealand Pharma, Zivo Bioscience, Zylo Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.

We found other products you might like!